Genetic polymorphisms in metabolizing enzymes can lead to interindividual variability in drug response and toxicity. For example, variations in genes encoding cytochrome P450 enzymes can result in poor, intermediate, extensive, or ultra-rapid metabolizer phenotypes, affecting drug clearance rates and risk of adverse effects. Personalized medicine seeks to account for these genetic differences to optimize therapeutic outcomes and minimize toxicity.
